文献速递乳房整形与再造创面修复

氨甲环酸在乳房切除与乳房再造中的应用现状:系统综述与Meta分析

The current state of tranexamic acid in mastectomy and breast reconstruction: A systematic review and meta-analysis.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2025-03-12

该系统综述与Meta分析纳入13项研究共2115例患者,其中926例(44%)接受氨甲环酸(TXA)。TXA组术后血肿发生率为2.4%(18例),对照组为5.5%(53例),血肿形成风险降低60%(OR 0.40;95%CI [0.23-0.70],P=0.001)。TXA显著缩短引流时间1.2天并减少24小时引流量41.8mL,但未显著影响血清肿或手术部位感染率。

要点

  • TXA组术后血肿发生率2.4% vs 对照组5.5%,血肿形成风险降低60%(OR 0.40;95%CI [0.23-0.70],P=0.001)。
  • TXA显著缩短引流时间1.2天(MD -1.2;P=0.03)并减少24小时引流量41.8mL(MD -41.8;P=0.002)。
  • TXA对血清肿形成率和手术部位感染率无显著影响。

核心结论

  • TXA给药可显著减少术后血肿形成、缩短引流时间并减少24小时引流量,且不影响血清肿或手术部位感染率。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南,检索5个数据库,双人筛选关于乳房切除伴或不伴乳房再造中使用TXA的研究。
  • 共纳入13项研究,总计2115例患者,其中926例(44%)接受TXA;772例(83%)术中给药,632例(82%)为静脉给药。
  • 评估结局包括术后血肿、血清肿、手术部位感染(SSI)、引流量和引流时间;采用Mantel-Haenszel法计算比值比(OR),逆方差法计算均数差(MD)。

主要发现

  • TXA组术后血肿发生率为2.4%(18例),对照组为5.5%(53例),血肿形成风险降低60%(OR 0.40;95%CI [0.23-0.70],P=0.001)。
  • TXA给药显著缩短引流时间1.2天(MD -1.2;P=0.03),并减少24小时引流量41.8mL(MD -41.8;P=0.002)。
  • TXA给药对血清肿形成率或SSI率无显著影响。

关键数值与推荐

  • TXA组血肿发生率2.4%(n=18)vs 对照组5.5%(n=53),OR 0.40(95%CI [0.23-0.70],P=0.001)。
  • 引流时间MD -1.2天(P=0.03);24小时引流量MD -41.8mL(P=0.002)。
  • 血清肿和SSI率无显著差异(原文未报告具体数值与统计量)。

临床怎么用

  • 原文结论为TXA给药可显著减少术后血肿形成、缩短引流时间并减少24小时引流量,且不影响血清肿或SSI率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of tranexamic acid (TXA) in breast surgery has been increasing; however, there have been no recent studies synthesizing the most current data. The purpose of this study was to perform a comprehensive targeted analysis on the impact of TXA in mastectomy with and without breast reconstruction. METHODS: A systematic review was conducted according to the preferred reporting items for systematic reviews and meta-analysis guidelines. Five databases were queried to identify studies using TXA in breast surgery. Dual-screening was employed to identify studies on mastectomy with and without breast reconstruction for full-text evaluation. Outcomes assessed included postoperative hematoma, seroma, surgical site infection (SSI), drain output, and drain duration. Data were pooled, and meta-analysis was performed. Odds ratios (OR) and mean differences (MD) were reported via the Mantel-Haenszel and Inverse-Variance methods, respectively. RESULTS: Thirteen studies totaling 2115 patients were included, with 44% of the patients (n=926) receiving TXA. Overall, 83% of the patients (n=772) received TXA intraoperatively and 82% of (n=632) received intravenous administration. Postoperative hematoma occurred in 2.4% of the patients (n=18) in the TXA group compared to 5.5% of the patients (n=53) in the control group, representing 60% decreased odds (OR 0.40; 95% CI [0.23-0.70], P = 0.001) of hematoma formation. TXA administration significantly reduced drain duration and 24-hour drain output by 1.2 days and 41.8 mL, respectively (MD: -1.2; P = 0.03; MD: -41.8; P = 0.002). TXA administration did not significantly impact the rates of seroma formation or SSI. CONCLUSION: TXA administration was found to significantly reduce postoperative hematoma formation, drain duration, and 24-hour drain output, without impacting seroma or SSI rates.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Fung E, Godek M, Roth JM, et al. The current state of tranexamic acid in mastectomy and breast reconstruction: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2025. PMID: 40156946. doi:10.1016/j.bjps.2025.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。